Vietnam vs Zimbabwe: Average cost of drugs for extensively drug-resistant tuberculosis
Vietnam
807 constant 2022 US$
in 2024
Zimbabwe
852 constant 2022 US$
in 2023
Vietnam rank
46th
Zimbabwe rank
45th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Vietnam
- Zimbabwe
How they compare
Zimbabwe currently reports 852 constant 2022 US$ against 807 constant 2022 US$ in Vietnam, a difference of 45 constant 2022 US$.
That makes Zimbabwe's figure about 1.1 times Vietnam's.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Zimbabwe ahead.
Vietnam ranks 46th and Zimbabwe ranks 45th of 56 countries.
Across the 2 decades both report, Vietnam averaged higher in 1 and Zimbabwe in 1.
Head to head by decade
| Decade | Vietnam | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,643 constant 2022 US$ | 8,999 constant 2022 US$ | 4,356 constant 2022 US$ | Zimbabwe |
| 2020s | 2,418 constant 2022 US$ | 917.33 constant 2022 US$ | 1,500 constant 2022 US$ | Vietnam |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Vietnam or Zimbabwe?
- Zimbabwe, at 852 constant 2022 US$ against 807 constant 2022 US$ in Vietnam as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Vietnam and Zimbabwe?
- 45 constant 2022 US$, with Zimbabwe ahead.
- How many years of comparable data are there for Vietnam and Zimbabwe?
- 6 years are reported by both, from 2017 to 2023.
- How do Vietnam and Zimbabwe rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Vietnam ranks 46th and Zimbabwe ranks 45th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.